Why is SPARC falling/rising?

As of 17-Jul, Sun Pharma Advanced Research Company Ltd's stock is currently priced at 161.45, reflecting a decrease of 1.7, or 1.04%. The stock has underperformed its sector today by 1.46% and has experienced a trend reversal after four consecutive days of gains. Despite a recent 3.53% increase over the past week, the stock has shown significant underperformance over the longer term, with a year-to-date decline of 19.38% and a one-year return of -31.86%. The company's financial health is concerning, as indicated by its negative book value and weak long-term growth metrics, including a decline in net sales and operating profit over the last five years. Additionally, the stock's risk profile is heightened due to a negative EBITDA and poor ability to service debt, which may contribute to investor caution.
In the broader market context, while the Sensex has gained 5.27% year-to-date, SPARC's performance has lagged significantly, indicating a consistent underperformance against the benchmark over the last three years. The stock's recent price movement reflects a challenging environment, as it has not only fallen today but has also struggled to maintain momentum despite rising investor participation, evidenced by a 22.6% increase in delivery volume. This juxtaposition of rising trading activity against a backdrop of poor financial fundamentals suggests that investors may be reacting to the company's ongoing struggles, leading to a cautious outlook on its future performance.